CLSA Continues to Engage with California Delegation to Protect Patent Rights, Oppose H.R. 9
July 7, 2015
CLSA is opposing H.R. 9, the so-called Innovation Act, legislation introduced by House Judiciary Committee Chairman Bob Goodlatte (R-Va.). In its current form, the legislation contains patent litigation-related provisions that would threaten the ability of biomedical innovators to enforce their patents and fund continued R&D by inadvertently making it more difficult, time-consuming and expensive to enforce legitimate and important IP rights.
The House is expected to consider the legislation before the August recess and CLSA has been actively engaging with the California delegation to inform members and staff about the negative impact that this legislation would have on the life sciences sector.
CLSA is also supporting a congressional sign-on letter led by Reps. Scott Peters (D-San Diego) and Ryan Costello (R-Penn.) highlighting the need for important reforms to the USPTO’s inter partes review and post grant review processes, and urging that these reforms be included in any patent legislation that is considered by the House. The letter is still open for signatures, and will be posted on our website here once finalized.
Earlier this spring CLSA organized a letter cosigned by more than 100 California life sciences organization opposing the legislation in its current form. A copy of the letter is available here.
CLSA will continue to engage on this issue and urge that the bill ultimately brought to the floor be more supportive of our state’s innovative life sciences sector. Click here to view CLSA’s statement on H.R. 9.